BR112012003059A2 - inibidores de jnk - Google Patents
inibidores de jnkInfo
- Publication number
- BR112012003059A2 BR112012003059A2 BR112012003059A BR112012003059A BR112012003059A2 BR 112012003059 A2 BR112012003059 A2 BR 112012003059A2 BR 112012003059 A BR112012003059 A BR 112012003059A BR 112012003059 A BR112012003059 A BR 112012003059A BR 112012003059 A2 BR112012003059 A2 BR 112012003059A2
- Authority
- BR
- Brazil
- Prior art keywords
- jnk inhibitors
- jnk
- inhibitors
- Prior art date
Links
- 239000012825 JNK inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23252209P | 2009-08-10 | 2009-08-10 | |
| PCT/EP2010/061476 WO2011018417A1 (en) | 2009-08-10 | 2010-08-06 | Inhibitors of jnk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012003059A2 true BR112012003059A2 (pt) | 2016-08-02 |
Family
ID=42710723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012003059A BR112012003059A2 (pt) | 2009-08-10 | 2010-08-06 | inibidores de jnk |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8536172B2 (https=) |
| EP (1) | EP2464640A1 (https=) |
| JP (1) | JP5784604B2 (https=) |
| KR (1) | KR101506318B1 (https=) |
| CN (1) | CN102471319B (https=) |
| AR (1) | AR077820A1 (https=) |
| AU (1) | AU2010283769B2 (https=) |
| BR (1) | BR112012003059A2 (https=) |
| CA (1) | CA2768749A1 (https=) |
| IL (1) | IL217756A0 (https=) |
| IN (1) | IN2012DN01231A (https=) |
| MX (1) | MX2012001449A (https=) |
| SG (1) | SG178321A1 (https=) |
| TW (1) | TW201109336A (https=) |
| WO (1) | WO2011018417A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012030814A2 (pt) * | 2010-06-04 | 2019-09-24 | Hoffmann La Roche | inibidores de jnk |
| US9062026B2 (en) * | 2012-07-20 | 2015-06-23 | Cleave Biosciences, Inc. | Fused pyrimidines and substituted quinazolines as inhibitors of p97 |
| ES2870085T3 (es) * | 2013-06-26 | 2021-10-26 | Xigen Inflammation Ltd | Inhibidores peptídicos permeables a células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis |
| CN106458990B (zh) | 2014-04-04 | 2019-06-07 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| WO2016100909A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF |
| CA2979534A1 (en) * | 2015-03-13 | 2016-09-22 | Abbvie Inc. | (indazol-4-yl)hexahydropyrrolopyrrolones and method of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2066319B1 (en) * | 2006-09-08 | 2012-02-01 | F. Hoffmann-La Roche AG | Benzotriazole kinase modulators |
| CN101547917A (zh) * | 2006-12-08 | 2009-09-30 | 霍夫曼-拉罗奇有限公司 | 用作jnk调节剂的取代的嘧啶类化合物及它们的应用 |
-
2010
- 2010-08-06 SG SG2012008819A patent/SG178321A1/en unknown
- 2010-08-06 AU AU2010283769A patent/AU2010283769B2/en not_active Ceased
- 2010-08-06 WO PCT/EP2010/061476 patent/WO2011018417A1/en not_active Ceased
- 2010-08-06 CN CN201080035300.3A patent/CN102471319B/zh not_active Expired - Fee Related
- 2010-08-06 EP EP10739948A patent/EP2464640A1/en not_active Withdrawn
- 2010-08-06 IN IN1231DEN2012 patent/IN2012DN01231A/en unknown
- 2010-08-06 JP JP2012524207A patent/JP5784604B2/ja not_active Expired - Fee Related
- 2010-08-06 MX MX2012001449A patent/MX2012001449A/es active IP Right Grant
- 2010-08-06 KR KR1020127006275A patent/KR101506318B1/ko not_active Expired - Fee Related
- 2010-08-06 CA CA2768749A patent/CA2768749A1/en not_active Abandoned
- 2010-08-06 BR BR112012003059A patent/BR112012003059A2/pt not_active IP Right Cessation
- 2010-08-09 TW TW099126517A patent/TW201109336A/zh unknown
- 2010-08-09 AR ARP100102908A patent/AR077820A1/es unknown
- 2010-08-09 US US12/852,540 patent/US8536172B2/en not_active Expired - Fee Related
-
2012
- 2012-01-26 IL IL217756A patent/IL217756A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201109336A (en) | 2011-03-16 |
| AU2010283769A1 (en) | 2012-02-09 |
| CN102471319B (zh) | 2014-06-18 |
| SG178321A1 (en) | 2012-03-29 |
| MX2012001449A (es) | 2012-03-26 |
| AR077820A1 (es) | 2011-09-28 |
| US8536172B2 (en) | 2013-09-17 |
| CN102471319A (zh) | 2012-05-23 |
| WO2011018417A1 (en) | 2011-02-17 |
| IN2012DN01231A (https=) | 2015-05-15 |
| EP2464640A1 (en) | 2012-06-20 |
| CA2768749A1 (en) | 2011-02-17 |
| US20110034470A1 (en) | 2011-02-10 |
| IL217756A0 (en) | 2012-03-29 |
| KR101506318B1 (ko) | 2015-03-26 |
| JP2013501746A (ja) | 2013-01-17 |
| AU2010283769B2 (en) | 2015-09-17 |
| JP5784604B2 (ja) | 2015-09-24 |
| KR20120055645A (ko) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2020023I1 (el) | Αναστολεiς βητα-λακταμασων | |
| DK2506745T3 (da) | Patron-ekstraktionsindretning | |
| BR112012004536A2 (pt) | dispositivo | |
| DK2414015T3 (da) | Laryngoskopsystem | |
| UA19989S (uk) | Пристрій гіпертермомасажний | |
| EP2440486A4 (en) | CABLE RETRACTION SYSTEM | |
| BR112012010974A2 (pt) | dispositivo | |
| BRPI1008827A2 (pt) | deisobutenizador | |
| FI20096144A0 (fi) | Ulkovalaisu | |
| BRPI0918564A2 (pt) | inibidores | |
| BRPI1014968A2 (pt) | subalargador | |
| DE112009005462T8 (de) | Lenkungsssteuervorrichtung | |
| BR112012004964A2 (pt) | girocóptero | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| FI20095891A0 (fi) | Polttomoottorisovitelma | |
| DK2493768T3 (da) | Etiketfjernelses-indretning | |
| BR112012002883A2 (pt) | dispositivo | |
| BRPI1010159A2 (pt) | bistuti | |
| FI20095852A0 (fi) | Suuntaajalaite | |
| BR112012002889A2 (pt) | dispositivo | |
| BR112012003059A2 (pt) | inibidores de jnk | |
| BRPI0912564A2 (pt) | inibidores de jnk | |
| FI20095735A0 (fi) | Puhdistinrakenne | |
| DE112010003843T8 (de) | Lastansteuervorrichtung | |
| BR112012000125A2 (pt) | dispositivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |